1 Corporate Presentation FEBRUARY 2021 ©2020 ASSEMBLY BIOSCIENCES, INC. Cautionary Note Regarding Forward-Looking Statements The information in this presentation contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio's ability to initiate and complete clinical studies involving its HBV therapeutic product candidates, including studies contemplated by Assembly Bio's clini ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Hepatitis B Program Update Conference Call February 25, 2021 5:00 PM ET Company Participants Lauren Glaser - Senior Vice President of Investor Relations and Corporate Affairs John McHutchison - President and Chief Executive Officer Bill Delaney - Chief Scientific Officer Luisa Stamm - Chief Medical Officer Conference Call Participants Brian Skorney - Baird Raju Prasad - William Blair Michael Yee - Jefferies Geoffrey Porges - SVB Leerink Salim Syed - Mizuho Nicole Ger ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to___________. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 20-8729264 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to___________. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 20-8729264 (State o ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Assembly Biosciences’ HBV Portfolio Progress Conference Call May 7, 2020 4:30 PM ET Company Participants Amy Figueroa - Interim Investor Relations Consultant Dr. John McHutchison - CEO and President Dr. Luisa Stamm - CMO Tom Russo - CFO Richard Colonno - EVP and CSO Virology Operations Conference Call Participants Brian Skorney - Baird Brad Canino - SVB Leerink Michael Yee - Jefferies Salim Syed - Mizuho Raju Prasad - William Blair Operator Good afternoon and welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to___________. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 20-8729264 (State ...

SecuritiesRegisteredPursuant TitleofEachClass Stock,$0.001ParValue UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________ to __________ Commission File Number: 001-35005 ASSEMBLY BIOSCIENCES, INC. (Exact name of registra ...